Ref: Syn/CS/SE/IP/2020-21/July/41 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC01493 July 21, 2020 www.syngeneintl.com To, To, The Manager Listing The Manager Listing BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Dear Sir/Madam, Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed the Investor Presentation for the quarter ended June 30, 2020. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to September 30, 2020. The above-mentioned Investor Presentation will also be available on website of the Company www.syngeneintl.com. This is for your information and records. Thanking You, Yours faithfully, For SYNGENE INTERNATIONAL LIMITED Digitally signed by PRIYADARSHIN PRIYADARSHINI MAHAPATRA I MAHAPATRA Date: 2020.07.21 ____________ 22:31:50 +05'30' Priyadarshini Mahapatra Company Secretary & Compliance Officer Enclosed: Investor Presentation
Investor Presentation July 21, 2020 Strictly confidential and privileged
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Putting Science to Work 2
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Q1FY21 Revenue Rs. 4,369 Mn; EBITDA Rs. 1,398 Mn; PAT Rs. 580 Mn Operating Highlights Financial Highlights ▪ Quarterly revenue from operations of Rs. 4,216 Mn, ▪ CRISIL long term rating upgraded from Crisil AA to Crisil marginally up on the corresponding quarter last year, AA+ with a stable outlook - an indication of Syngene’s impacted due to the temporary suspension of operations strong fundamentals, sound business model and robust during the nationwide lockdown liquidity position ▪ Implementation of protective measures post COVID-19 has allowed to operate at close to normal levels for the last six EBITDA Total Revenue weeks of the quarter and enabled to get client projects Rs. 4,369 Mn Rs 1,398 Mn back on schedule ▪ First quarter performance was driven by solid Profit After Tax EBITDA Margin at 32% performances in Discovery Services and the Dedicated PAT Margin at 13% Rs. 580 Mn Centres Putting Science to Work 5
Q1FY21 Financial Performance All figures in Rs. Mn unless otherwise specified ▪ Revenues from operations increased by 0.2% led by growth P&L Summary Q1 FY21 Q1 FY20 YoY Change in Discovery Services, supported by steady traction in the Dedicated R&D Centre business Revenue from operations 4,216 4,209 0.2% ▪ Other income declined on account of the reduction in cash balances with the repayment of USD 37.5 Mn ECB loan in Other Income 153 205 (25%) March 2020 and a reduction in yield rates on deposits Total Revenue 4,369 4,414 (1%) ▪ EBITDA Margin maintained at 32% driven by savings in raw material costs and certain operational efficiencies, partially EBITDA 1,398 1,416 (1%) offset by increase in staff costs EBITDA Margin 32% 32% ▪ Depreciation increased by 39% to Rs. 661 Mn from Rs.474 Mn in the same period last year due to investments in new facilities PAT 580 720 (19%) ▪ Very strong liquidity and cash position to fund capex plans PAT Margin 13% 16% – Net cash as on 30 st June, 2020 at Rs 3,950 Mn Putting Science to Work 6
Update on COVID-19 Priorities in these uncertain times Introduction of shift operations, work from home where possible and other protection measures for employees allowed operations to return to near normal levels Safety and wellbeing Client projects of our people back on schedule ▪ National lockdown resulted in a temporary suspension of operations; invoked BCP to resume operations Resilient supply Focus on operating chain in place efficiencies ▪ Currently operating at 90+% capacity ▪ Leveraged IT solutions and technology to facilitate COVID research projects seamless onsite and remote operations ▪ RT-PCR testing lab has tested more than 30,000 samples free ▪ Implemented various initiatives to keep the workplace of charge so far safe - zoning on site to restrict movements; compulsory ▪ Indigenously developed an ELISA testing kit ; tie-up with twice-daily temperature checks; social distancing in HiMedia for mass manufacturing and distribution canteens and in company transport; shift system to reduce density on site ▪ Collaboration with Centre for Cellular and Molecular Biology ( CCMB) for NGS based testing Putting Science to Work 7
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Putting science to work Who we are and what we do ▪ Offering integrated research, development and manufacturing services to take projects from early discovery to commercial supply ▪ Working with clients from around the world to find solutions to their scientific challenges for small and large molecules while improving productivity, speeding up time to market and lowering cost of innovation ▪ Innovative culture driven by the expertise of a highly qualified team of 5,000 employees and supported by state-of-the-art infrastructure and market-leading technology Putting Science to Work 9
Syngene key facts and figures All figures are as on March 31, 2020, unless otherwise specified 8 collaborations 400+ Patents 360+ active clients with top 10 pharmaceutical held with clients companies 4200+ talented team of 1.9 Mn sq. ft. 90% employees scientists of World class infrastructure, in 25-40 year age qualified to meet international Including ~460 PhDs bracket standards Rs. 20,935 Mn Rs. 3,662 Mn Rs. 31,541 Mn Revenue for FY20 PAT for FY20 Capex Investment as on March 2020 Putting Science to Work 10
The Syngene advantage Integrated service provider offering end-to-end Flexible and varied business models drug discovery, development and manufacturing To cater to client requirement services on a single platform Experienced in successfully managing large International accreditations relationships OHSAS 18001 Certified Facilities, GLP, cGMP, AAALAC & CPCSEA Certified Facility Talented & experienced scientific and 25+ years of unparalleled experience techno-commercial teams with significant management bandwidth Putting Science to Work 11
Our experience spans multiple industry segments and partnerships with global leaders across the world Client Base FY 20 362 • Four leading US, Asian, European chemicals and FY 19 331 polymer manufacturing FY 18 316 companies • Leading China based • Germany crop protection headquartered FY 17 293 company company , one of the • • Global food and Large Japanese largest chemical beverage company chemical company FY 16 256 producers in the • world Large MNC focussed • US based company , on Agriculture & one of the largest Nutrition segments Client footprint* (%) chemical producers in the world US • Large Asian chemical 5 4 3 corporation Europe 12 Japan India Large & Mid- 76 Chemicals/ Rest of Sized BioPharma Polymers Animal Health AgroChem CPG World Putting Science to Work 12 Note: Clients mentioned are only representative. Syngene had 362 clients in FY20 *Based on FY20 Sales
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Recommend
More recommend
